Expiration Date: January 21, 2017
Media: Print with online posttest, evaluation, and request for credit
This activity is designed to inform physicians about the latest treatment advances in metastatic melanoma, including approved and investigational management strategies.
Instructions For This Activity & Receiving Credit
This activity is directed toward medical oncologists, primary care physicians, nurses, and nurse practitioners who treat patients with melanoma. Dermatologists, surgical oncologists, radiation oncologists, pathologists, fellows, physician assistants, and other healthcare providers interested in the management of melanoma are also invited to participate.
Learning ObjectivesAfter participating in this CME activity, learners should be better prepared to:
- Review FDA approvals for melanoma since 2011
- Explain the mechanism by which combining a BRAF inhibitor with a MEK inhibitor increases responses/survival and decreases toxicities
- Describe the differences in toxicities between vemurafenib and dabrafenib
- Summarize pivotal data coming out of the CheckMate trials
- Discuss the factors involved in the choice between monotherapy and combination therapy for first-line treatment of metastatic melanoma
The American Journal of Hematology/ Oncology® Editorial Board
Debu Tripathy, MD
Professor of Medicine and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, Oncoplex Diagnostics, Merck, and Novartis.
Antoni Ribas, MD, PhD
Professor of Medicine
Professor of Surgery Professor of Molecular and Medical Pharmacology Director
Tumor Immunology Program
David Geffen School of Medicine University of California
Jonsson Comprehensive Cancer Center
Los Angeles, CA
Disclosure: Amgen Inc; Genentech; GlaxoSmithKline; Merck & Co, Inc; Roche; stock/Shareholder: Kite Pharma, Inc; Compugen; CytomX.
Staff/Planner Disclosures and Conflict of Interest Resolution
The staff of Physicians' Education Resource®, LLC, (PER®) and the editorial staff of The American Journal of Hematology/Oncology® have no relevant financial relationships with commercial interests to disclose.
In accordance with Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial SupportSM, PER® resolved all conflicts of interest prior to the release of this CME activity using a multistep process.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for CME purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
DisclaimerThe opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Hardware And Software RequirementsSupported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise